Alcoholic hepatitis

Global Alcoholic Hepatitis Pipeline Review 2021: Drugs In Development - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 19, 2021
Health, General Health, Health care, ROA, Therapy, Mall of America, Medication, Discovery, SEC, Research, Decision-making, R, News, History, Alcoholic hepatitis, Company, Pharmaceutical industry

The pipeline guide also reviews of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects.

Key Points: 
  • The pipeline guide also reviews of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide reviews key companies involved in Alcoholic Hepatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

Global Liver Institute Announces First Annual Rare Liver Diseases Month

Retrieved on: 
Monday, February 1, 2021
Medical specialties, Hepatitis, Clinical medicine, Steatohepatitis, Non-alcoholic fatty liver disease, Fatty liver disease, Alcoholic liver disease, Liver disease, Liver, Alcoholic hepatitis, Melissa Palmer, Foundation for Liver Research

Washington, DC, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI), in their mission to improve the lives of individuals and families impacted by liver disease, has announced February 2021 as the first annual Rare Liver Diseases Month.

Key Points: 
  • Washington, DC, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI), in their mission to improve the lives of individuals and families impacted by liver disease, has announced February 2021 as the first annual Rare Liver Diseases Month.
  • There are over 100 liver diseases, yet most liver diseases are often overshadowed by more common liver diseases such as alcoholic hepatitis, viral hepatitis, and non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) due to their prevalence.
  • With Rare Liver Diseases Month and the #RareAware campaign, GLI aims to shine a light on these terrible diseases, raising awareness, and illuminating the need for policies and research that support rare liver patients.
  • In addition, in honor of Rare Liver Diseases Month, GLIs weekly online virtual event, GLI LIVE, hosted by Mrs. Cryer, airing live on Facebook, YouTube, and Periscope every Wednesday at 12pm EST, will focus on rare liver diseases.

World Alcoholic Hepatitis Market Epidemiology and Forecasts to 2030

Retrieved on: 
Tuesday, December 22, 2020
Medical specialties, Clinical medicine, Immunology, Healthcare-associated infections, Hepatitis, Alcoholic hepatitis

What was the Alcoholic Hepatitis market share (%) distribution in 2017, and how it would look like in 2030?

Key Points: 
  • What was the Alcoholic Hepatitis market share (%) distribution in 2017, and how it would look like in 2030?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest Alcoholic Hepatitis market size during the forecast period (2017-2030)?
  • What would be the Alcoholic Hepatitis market growth until 2030, and what will be the resultant market size in the year 2030?
  • What are the disease risks, burdens, and unmet needs of Alcoholic Hepatitis?

Alcoholic Hepatitis Market Insights, Epidemiology and Market Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 16, 2020
Health, Infectious diseases, Medical specialties, Clinical medicine, Immunology, Healthcare-associated infections, Hepatitis, Alcoholic hepatitis

What was the Alcoholic Hepatitis market share (%) distribution in 2017, and how it would look like in 2030?

Key Points: 
  • What was the Alcoholic Hepatitis market share (%) distribution in 2017, and how it would look like in 2030?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest Alcoholic Hepatitis market size during the forecast period (2017-2030)?
  • What would be the Alcoholic Hepatitis market growth until 2030, and what will be the resultant market size in the year 2030?
  • What are the disease risks, burdens, and unmet needs of Alcoholic Hepatitis?

Alcoholic Hepatitis Epidemiology Forecast to 2030 - Current Available Treatments - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 3, 2020
Infectious diseases, Hospitals, Health, Other Health, Medical specialties, Clinical medicine, Medicine, Healthcare-associated infections, Hepatitis, Alcoholic hepatitis, Epidemiology, Infectious causes of cancer, World Hepatitis Day

The Alcoholic Hepatitis epidemiology report gives a thorough understanding of Alcoholic Hepatitis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis.

Key Points: 
  • The Alcoholic Hepatitis epidemiology report gives a thorough understanding of Alcoholic Hepatitis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis.
  • This section encompassing Alcoholic Hepatitis epidemiology provides insights about historical and current patient pool and forecasted trends for every seven major countries.
  • The Alcoholic Hepatitis epidemiology covered in the report provides historical as well as forecasted Alcoholic Hepatitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
  • The Alcoholic Hepatitis Epidemiology report will allow the user to:
    Develop business strategies by understanding the trends shaping and driving the global Alcoholic Hepatitis market.

DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer

Retrieved on: 
Monday, November 2, 2020
Medical specialties, Hepatitis, Clinical medicine, Medicine, Steatohepatitis, Non-alcoholic fatty liver disease, Liver disease, Alcoholic hepatitis

as its Chief Medical Officer, effective immediately.

Key Points: 
  • as its Chief Medical Officer, effective immediately.
  • In this new role, Dr. Sussman will oversee the clinical development of DURECT's pipeline including multiple indications for its lead investigational drug candidate DUR-928.
  • "We are excited to welcome Dr. Sussman as our Chief Medical Officer as we continue to advance DUR-928 through clinical development for the treatment of alcoholic hepatitis (AH), nonalcoholic steatohepatitis (NASH), and other indications," stated James E. Brown, D.V.M., President and Chief Executive Officer of DURECT.
  • "Dr. Sussman is a renowned hepatologist with a proven track record in clinical research of liver diseases.

DURECT Corporation Announces Presentation of Phase 2a Pharmacokinetic Data of DUR-928 in Alcoholic Hepatitis at Digital International Liver Congress (EASL)

Retrieved on: 
Thursday, August 27, 2020
Immunology, RTT, Hepatitis, Alcoholic hepatitis

CUPERTINO, Calif., Aug. 27, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the presentation of pharmacokinetic (PK) data from a Phase 2a study of DUR-928 in alcoholic hepatitis (AH) at the Digital International Liver Congress 2020 (EASL) , takingplace on August 27-29.

Key Points: 
  • CUPERTINO, Calif., Aug. 27, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the presentation of pharmacokinetic (PK) data from a Phase 2a study of DUR-928 in alcoholic hepatitis (AH) at the Digital International Liver Congress 2020 (EASL) , takingplace on August 27-29.
  • DUR-928 was well tolerated at all doses tested in 19 AH patients, including 12 severe AH patients.
  • DURECT is finalizing its preparations to initiate a multi-center, international, randomized, double blind, placebo-controlled Phase 2b clinical trial of DUR-928 in severe AH patients later this year.
  • From a recent publication analyzing the mortality and costs associated with alcoholic hepatitis, the cost per patient is estimated at over$50,000in the first year.

Alcoholic Hepatitis Treatment Market Highlights the Impact of COVID-19 (2020-2024) | Increasing Consumption of Alcohol to Boost Market Growth | Technavio

Retrieved on: 
Tuesday, August 11, 2020
Health, General Health, RTT, Medical specialties, Clinical medicine, Health, Hepatitis, Alcoholic hepatitis, Alcoholism

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • Availability of prognostic models for alcoholic hepatitis is a major growth factor for the market.
  • Increasing consumption of alcohol and availability of prognostic models for alcoholic hepatitis are the major factors driving the market.
  • Alcoholic Hepatitis Treatment Market 2020-2024: Segmentation
    Alcoholic Hepatitis Treatment Market is segmented as below:

Global Alcoholic Hepatitis Pipeline Monitor, 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 29, 2020
Health, Pharmaceutical, Medical specialties, Health, Hepatitis, RTT, Pipeline, Drug pipeline, Alcoholic hepatitis

The "Alcoholic Hepatitis Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alcoholic Hepatitis Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.
  • Global Alcoholic Hepatitis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates.
  • This Alcoholic Hepatitis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
  • The competitive intelligence report on Alcoholic Hepatitis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Alcoholic Hepatitis pipeline.

The Global Alcoholic Hepatitis Treatment Market is expected to grow by $ 613.42 mn during 2020-2024 progressing at a CAGR of 6% during the forecast period

Retrieved on: 
Monday, June 8, 2020
Hepatitis, RTT, Alcoholic hepatitis, Trend

The analyst has been monitoring the alcoholic hepatitis treatment market and it is poised to grow by $ 613.42 mn during 2020-2024 progressing at a CAGR of 6% during the forecast period.

Key Points: 
  • The analyst has been monitoring the alcoholic hepatitis treatment market and it is poised to grow by $ 613.42 mn during 2020-2024 progressing at a CAGR of 6% during the forecast period.
  • Our reports on alcoholic hepatitis treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
  • The alcoholic hepatitis treatment market is segmented as below: